Table 1.
Baseline patient demographics and disease characteristics by PD-L1 subgroup.
| Durvalumab + EP (n = 152) | Durvalumab + tremelimumab + EP (n = 157) | EP (n = 129) | ||||
|---|---|---|---|---|---|---|
| TC and IC <1% (n = 114) | TC or IC ≥1% (n = 38) | TC and IC <1% (n = 103) | TC or IC ≥1% (n = 54) | TC and IC <1% (n = 97) | TC or IC ≥1% (n = 32) | |
| Median age (range), years | 62.5 (46–81) | 66.0 (40–78) | 63.0 (43–84) | 60.5 (36–83) | 63.0 (38–78) | 61.5 (42–80) |
| Age group, n (%) | ||||||
| <65 | 72 (63.2) | 17 (44.7) | 61 (59.2) | 34 (63.0) | 56 (57.7) | 21 (65.6) |
| ≥65 | 42 (36.8) | 21 (55.3) | 42 (40.8) | 20 (37.0) | 41 (42.3) | 11 (34.4) |
| Sex, n (%) | ||||||
| Men | 83 (72.8) | 28 (73.7) | 75 (72.8) | 38 (70.4) | 68 (70.1) | 21 (65.6) |
| Women | 31 (27.2) | 10 (26.3) | 28 (27.2) | 16 (29.6) | 29 (29.9) | 11 (34.4) |
| Race, n (%) | ||||||
| White | 97 (85.1) | 36 (94.7) | 87 (84.5) | 46 (85.2) | 79 (81.4) | 27 (84.4) |
| Asian | 14 (12.3) | 2 (5.3) | 15 (14.6) | 8 (14.8) | 14 (14.4) | 5 (15.6) |
| Black | 2 (1.8) | 0 | 0 | 0 | 2 (2.1) | 0 |
| Other or missing data | 1 (0.9) | 0 | 1 (1.0) | 0 | 2 (2.1) | 0 |
| Disease stage, n (%) | ||||||
| III | 13 (11.4) | 5 (13.2) | 5 (4.9) | 4 (7.4) | 8 (8.2) | 2 (6.3) |
| IV | 101 (88.6) | 33 (86.8) | 98 (95.1) | 50 (92.6) | 89 (91.8) | 30 (93.8) |
| WHO PS, n (%) | ||||||
| 0 | 36 (31.6) | 13 (34.2) | 42 (40.8) | 13 (24.1) | 29 (29.9) | 12 (37.5) |
| 1 | 78 (68.4) | 25 (65.8) | 61 (59.2) | 41 (75.9) | 68 (70.1) | 20 (62.5) |
| Smoking history, n (%) | ||||||
| Never smoker | 10 (8.8) | 4 (10.5) | 5 (4.9) | 6 (11.1) | 5 (5.2) | 2 (6.3) |
| Former smoker | 55 (48.2) | 15 (39.5) | 54 (52.4) | 28 (51.9) | 41 (42.3) | 12 (37.5) |
| Current smoker | 49 (43.0) | 19 (50.0) | 44 (42.7) | 20 (37.0) | 51 (52.6) | 18 (56.3) |
| Brain or CNS metastases, n (%) | 8 (7.0) | 4 (10.5) | 15 (14.6) | 10 (18.5) | 8 (8.2) | 4 (12.5) |
| Liver metastases, n (%) | 46 (40.4) | 9 (23.7) | 57 (55.3) | 16 (29.6) | 40 (41.2) | 12 (37.5) |
Abbreviations: CNS, central nervous system; EP, platinum-etoposide; IC, immune cell; PD-L1, programmed cell death ligand-1; PS, performance status; TC, tumor cell; WHO, World Health Organization.